PRLB Stock Analysis: Proto Labs | NYSE
Metal Fabrication | NYSE, USA | Market Cap: 1.991m USD | 12M Return: 68.3% | US7437131094 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.0M
EPS Trend: 54.6%
Qual. Beats: 0
Rev. Trend: 83.4%
Qual. Beats: 3
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Proto Labs, Inc. (NYSE: PRLB) is a U.S.-based digital manufacturer of custom parts, operating primarily in the United States and Europe. Founded in 1999 and headquartered in Maple Plain, Minnesota, the company went public on February 24, 2012, and is classified within the Industrials sector under the GICS Industrial Machinery & Supplies & Components sub-industry, with a small-cap market capitalization of approximately $1.93 billion.
The company provides on-demand manufacturing services spanning injection molding, computer numerical control (CNC) machining, 3D printing (additive manufacturing), and sheet metal fabrication. Its customer base consists primarily of product developers, design engineers, and supply chain teams who require low-volume, custom-manufactured components. Proto Labs operates within the broader digital manufacturing segment, which uses internet-enabled quoting and ordering workflows to produce prototype and low-volume production parts without requiring traditional tooling-heavy setup.
Proto Labs service mix positions it at the intersection of several industrial subsectors, including contract manufacturing and additive manufacturing. The company competes in a fragmented market against both regional job shops and other digital manufacturing platforms, with its integrated multi-process offering (covering plastics, metals, and additive techniques) distinguishing it from single-technology providers.
- CNC and molding revenue declines on industrial slowdown
- 3D Hubs marketplace expansion boosts margins and customer reach
- European demand softness pressures revenue and operating margins
| Net Income: 30.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -2.15 > 1.0 |
| NWC/Revenue: 34.44% < 20% (prev 28.18%; Δ 6.26% < -1%) |
| CFO/TA 0.10 > 3% & CFO 78.5m > Net Income 30.5m |
| Net Debt (-140.5m) to EBITDA (75.7m): -1.86 < 3 |
| Current Ratio: 3.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (24.4m) vs 12m ago 0.28% < -2% |
| Gross Margin: 45.42% > 18% (prev 44.17%; Δ 1.25% > 0.5%) |
| Asset Turnover: 73.06% > 50% (prev 68.43%; Δ 4.62% > 0%) |
| Interest Coverage Ratio: 69.71 > 6 (EBIT TTM 42.9m / Interest Expense TTM 616k) |
| A: 0.24 (Total Current Assets 266.2m - Total Current Liabilities 73.2m) / Total Assets 791.3m |
| B: 0.32 (Retained Earnings 254.3m / Total Assets 791.3m) |
| C: 0.06 (EBIT TTM 42.9m / Avg Total Assets 767.3m) |
| D: 6.95 (Book Value of Equity 691.7m / Total Liabilities 99.6m) |
| Altman-Z'' = 10.32 = AAA |
| DSRI: 1.11 (Receivables 96.5m/79.2m, Revenue 560.5m/508.6m) |
| GMI: 0.97 (GM 44.17% / 45.42%) |
| AQI: 0.93 (AQ_t 0.40 / AQ_t-1 0.43) |
| SGI: 1.10 (Revenue 560.5m / 508.6m) |
| TATA: -0.06 (NI 30.5m - CFO 78.5m) / TA 791.3m) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of September 18, 2026, the stock is trading at USD 83.24 with a total of 343,016 shares traded. Over the past week, the price has changed by +2.91%, over one month by -8.39%, over three months by +5.72% and over the past year by +68.33%.
Current recommended Stop Loss: 80.10 (which is 3.8% or 1.2 ATR below the current price).
Proto Labs has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold PRLB.
- StrongBuy: 2
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 95.5 | 14.7% |
P/E Trailing = 66.0635
P/E Forward = 32.2581
P/S = 3.5524
P/B = 2.8787
P/EG = 0.8585
Revenue TTM = 560.5m USD
EBIT TTM = 42.9m USD
EBITDA TTM = 75.7m USD
Long Term Debt = 1.19m USD (estimated: total debt 2.24m - short term 1.06m)
Short Term Debt = 1.06m USD (from shortTermDebt, last quarter)
Debt = 2.24m USD (from shortLongTermDebtTotal, last quarter) (leases 2.24m already included)
Net Debt = -140.5m USD (calculated: Debt 2.24m - CCE 142.8m)
Enterprise Value = 1.85b USD (1.99b + Debt 2.24m - CCE 142.8m)
Interest Coverage Ratio = 69.71 (Ebit TTM 42.9m / Interest Expense TTM 616k)
EV/FCF = 29.86x (Enterprise Value 1.85b / FCF TTM 62.0m)
FCF Yield = 3.35% (FCF TTM 62.0m / Enterprise Value 1.85b)
FCF Margin = 11.06% (FCF TTM 62.0m / Revenue TTM 560.5m)
Net Margin = 5.44% (Net Income TTM 30.5m / Revenue TTM 560.5m)
Gross Margin = 45.42% ((Revenue TTM 560.5m - Cost of Revenue TTM 305.9m) / Revenue TTM)
Gross Margin QoQ = 46.43% (prev 45.64%)
Tobins Q-Ratio = 2.34 (Enterprise Value 1.85b / Total Assets 791.3m)
Interest Expense / Debt = 27.49% (Interest Expense 616k / Debt 2.24m)
Taxrate = 27.99% (11.8m / 42.3m)
NOPAT = 30.9m (EBIT 42.9m * (1 - 27.99%))
Current Ratio = 3.64 (Total Current Assets 266.2m / Total Current Liabilities 73.2m)
Debt / Equity = 0.00 (Debt 2.24m / totalStockholderEquity, last quarter 691.7m)
Debt / EBITDA = -1.86 (Net Debt -140.5m / EBITDA 75.7m)
Debt / FCF = -2.27 (Net Debt -140.5m / FCF TTM 62.0m)
Total Stockholder Equity = 678.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.97% (Net Income 30.5m / Total Assets 791.3m)
RoE = 4.49% (Net Income TTM 30.5m / Total Stockholder Equity 678.4m)
RoCE = 6.32% (EBIT 42.9m / Capital Employed (Equity 678.4m + L.T.Debt 1.19m))
RoIC = 4.47% (NOPAT 30.9m / Invested Capital 691.1m)
WACC = 12.24% (E(1.99b)/V(1.99b) * Re(12.23%) + D(2.24m)/V(1.99b) * Rd(27.49%) * (1-Tc(0.28)))
Discount Rate = 12.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -84.36 | Cagr: -2.50%
[DCF] Terminal Value 60.08% ; FCFF base≈66.9m ; Y1≈58.7m ; Y5≈47.4m
[DCF] Fair Price = 25.36 (EV 466.1m - Net Debt -140.5m = Equity 606.7m / Shares 23.9m; r=12.24% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 54.57 | EPS CAGR: 4.71% | SUE: -0.44 | # QB: 0
Revenue Correlation: 83.37 | Revenue CAGR: 3.68% | SUE: 1.86 | # QB: 3
EPS current Quarter (2026-09-30): EPS=0.60 | Chg30d=+14.07% | Revisions=+57% | Analysts=5
EPS current Year (2026-12-31): EPS=2.21 | Chg30d=+8.53% | Revisions=+57% | GrowthEPS=+33.4% | GrowthRev=+9.2%
EPS next Year (2027-12-31): EPS=2.39 | Chg30d=+8.15% | Revisions=+57% | GrowthEPS=+7.8% | GrowthRev=+7.6%
[Analyst] Revisions Ratio: +80% (up=12, down=0)